Alpha 2.0
Login Register
» Authors » Mathilde Yakoub-Agha

Mathilde Yakoub-Agha

Explore the profile of Mathilde Yakoub-Agha including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 11
Followers 0
Related Specialties
Oncology
General Medicine
Anesthesiology
Top 10 Co-Authors
Celine Vicente
Anne-Sophie Moreau
Cecile Pochon
Corinne Courbon
Muriel Picard
Ibrahim Yakoub-Agha
Jean-Jacques Tudesq
Franciane Paul
Arthur Sterin
Jacques-Olivier Bay
Published In
Bull Cancer
J Cardiothorac Vasc Anesth
J Clin Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Prognostic Value of a New Right Ventricular-to-Pulmonary Artery Coupling Parameter Using Right Ventricular Longitudinal Shortening Fraction in Patients Undergoing Transcatheter Aortic Valve Replacement: A Prospective Echocardiography Study
Beyls C, Yakoub-Agha M, Hermida A, Martin N, Crombet M, Hanquiez T, et al.
J Clin Med . 2024 Feb; 13(4). PMID: 38398319
: Right-ventricular-to-pulmonary artery (RV-PA) coupling, measured as the ratio of tricuspid annular plane systolic excursion (TAPSE) to pulmonary artery systolic pressure (PASP), has emerged as a predictor factor in patients...
2.
Nonsteroidal Antiinflammatory Drugs Used in Cardiac Surgery: A Survey of Practices and New Insights for Future Studies
Abou-Arab O, Yakoub-Agha M, Moussa M, Mauriat P, Provenchere S, Fellahi J, et al.
J Cardiothorac Vasc Anesth . 2023 Nov; 38(1):349-351. PMID: 37949724
No abstract available.
3.
[Management of neurotoxicity following CAR-T cell therapy: Recommendations of the SFGM-TC]
Picard M, Sterin A, Bay J, Courbon C, Moreau A, Paul F, et al.
Bull Cancer . 2022 Jan; 110(2S):S123-S131. PMID: 35094839
The immune effector cell-associated syndrome (ICANS) has been described as the second most frequent specific complication following CAR-T cell therapy. The median time to the onset of neurological symptoms is...
4.
[Management of cytokine release syndrome and macrophage activation syndrome following CAR-T cell therapy: Guidelines from the SFGM-TC]
Tudesq J, Yakoub-Agha M, Bay J, Courbon C, Paul F, Picard M, et al.
Bull Cancer . 2021 Dec; 110(2S):S116-S122. PMID: 34895696
The use of chimeric antigen receptor T cells (CAR-T) has increased since their approval in the treatment of several relapsed/refractory B cell malignancies. The management of their specific toxicities, such...
5.
[Prevention and management of infections in patients undergoing CAR T-cell therapy: Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]
Paul F, Vicente C, Courbon C, Moreau A, Picard M, Pochon C, et al.
Bull Cancer . 2021 Dec; 108(12S):S90-S97. PMID: 34876272
Infections occurring after CAR T-cells are a common complication. At the acute phase of treatment following CAR T-cell infusion, the exact incidence of infections is unknown given the overlapping symptoms...
6.
[Complications other than infections, CRS and ICANS following CAR T-cells therapy: Recommendations of the Francophone Society of bone marrow transplantation and cell therapy (SFGM-TC)]
Pochon C, Courbon C, Bay J, Moreau A, Paul F, Picard M, et al.
Bull Cancer . 2021 Nov; 108(12S):S98-S103. PMID: 34802718
CAR-T cells are an innovative treatment for an increasing number of patients, particularly since the extension of their indication to mantle lymphoma and multiple myeloma. Several complications of CAR T-cell...